Peptide drugs are not a speculative category waiting for legitimacy. They are already established in medicine.

That matters because public awareness of the category is often much narrower than the category itself. Insulin is a peptide drug. Other approved peptide drugs are used across areas such as metabolism, endocrinology, and pain.

The more useful takeaway is not just that approvals exist. It is that peptide signaling has already proved medically workable across multiple contexts.

It keeps the reader from mistaking visibility for novelty.

That broader footing matters when newer peptide-based drugs become prominent.